

	Placebo		Xanomeline Low Dose		Xanomeline High Dose	
	n	(%)	n	(%)	n	(%)
Participants in population	86		84		84	
Completed	58	67.4	25	29.8	27	32.1
Discontinued	28	32.6	59	70.2	57	67.9
Adverse Event	8	9.3	44	52.4	40	47.6
Death	2	2.3	1	1.2	0	0.0
I/E Not Met	1	1.2	0	0.0	2	2.4
Lack of Efficacy	3	3.5	0	0.0	1	1.2
Lost to Follow-up	1	1.2	1	1.2	0	0.0
Physician Decision	1	1.2	0	0.0	2	2.4
Protocol Violation	1	1.2	1	1.2	1	1.2
Sponsor Decision	2	2.3	2	2.4	3	3.6
Withdrew Consent	9	10.5	10	11.9	8	9.5